低剂量兰地洛尔不能预防非亚洲患者心脏术后房颤
这项在法国三中心开展的多中心、双盲、随机、安慰剂对照优效性试验纳入318例≥65岁非亚洲择期心脏手术患者,发现低剂量兰地洛尔24小时输注并未降低ICU内术后房颤发生率(29.8% vs 31.9%,RR 0.93,95%CI 0.67-1.30,P=0.77),次要终点及安全性亦无差异。
要点
- 非亚洲心脏手术患者中低剂量兰地洛尔未降低ICU内术后房颤。
- 术后房颤发生率兰地洛尔组29.8%,安慰剂组31.9%,无统计学差异。
- 住院期间房颤及安全性结局两组亦无差异。
核心结论
- 在非亚洲冠脉搭桥或瓣膜手术患者中,低剂量兰地洛尔24小时输注作为口服β受体阻滞剂的桥接治疗,未减少术后房颤发生率。
研究设计与样本
- 多中心、双盲、随机、安慰剂对照优效性试验,2021年1月至2023年7月在法国三家医院开展。
- 纳入318例≥65岁非亚洲择期心脏手术患者,均使用体外循环且左室射血分数≥40%。
- 治疗于ICU启动并持续至多24小时,随后给予口服β受体阻滞剂。
主要发现
- ICU内术后房颤发生率:安慰剂组51/160(31.9%),兰地洛尔组47/158(29.8%),RR 0.93(95%CI 0.67-1.30),P=0.77。
- 住院期间术后房颤、ICU及住院时长、安全性结局均无差异。
关键数值与推荐
- 主要终点为ICU内术后房颤发生率,按意向性分析。
- 兰地洛尔用法为低剂量持续静脉输注,具体剂量原文未在本摘要中给出。
临床怎么用
- 对于非亚洲心脏手术患者,不应常规使用低剂量兰地洛尔来预防术后房颤。
- 仍需遵循指南以β受体阻滞剂作为术后房颤预防的一线选择。
局限性
- 研究仅纳入非亚洲患者,结果不能外推至亚洲人群。
- 样本量318例,可能不足以检测小幅差异。
- 具体兰地洛尔剂量未在本摘要中报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative atrial fibrillation (POAF) affects 30% of patients undergoing cardiac surgery with cardiopulmonary bypass (CPB). Beta-blockers are the first-line agents recommended for POAF prevention. Landiolol, an ultra-short-acting, highly selective beta-1-blocker, has been shown to be effective in reducing POAF in Asian patients at a low dose of 2 μg kg-1 min-1. The aim of this study was to evaluate the effect of a low dose of landiolol for the prevention of POAF in non-Asian patients after cardiac surgery. METHODS: This multicentre, double-blind, randomised, placebo-controlled superiority trial was conducted from January 2021 to July 2023 at three hospitals in France. Participants were non-Asians ≥65 yr undergoing elective cardiac surgery with CPB and a left ventricular ejection fraction ≥40%. Treatment was started in the ICU and continued for up to 24 h, after which oral beta-blockers were administered. The primary endpoint was the incidence of POAF while in the ICU, analysed by intention to treat. Secondary outcomes included in-hospital and 30-day POAF, ICU and hospital length of stay, and safety outcomes. RESULTS: A total of 318 participants (mean age: 71 [range: 68-76] yr; 21.4% female) were randomised. POAF in ICU occurred in 51/160 (31.9%) participants who received placebo, compared with 47/158 (29.8%) who received a low-dose landiolol infusion (relative risk: 0.93 [95% confidence interval, 0.67-1.30]; P=0.77). No differences were observed in secondary endpoints, including in-hospital POAF and safety outcomes. CONCLUSIONS: In non-Asian patients undergoing cardiac surgery with CPB, a low-dose 24-h infusion of landiolol, used as a bridge to oral beta-blockers, did not reduce the incidence of postoperative atrial fibrillation. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov (NCT04607122).
引用
- Amour J, Naudin C, Besnard A, et al. Low dose of landiolol does not prevent postoperative atrial fibrillation after cardiac surgery in non-Asian patients: a multicentre randomised study. Br J Anaesth. 2025. PMID: 41203473. doi:10.1016/j.bja.2025.09.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。